Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
4,72 USD | -8,70% | -9,06% | -9,92% |
Attività
Numero di dipendenti: 88
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Novel Integrated Drug and Drug Delivery Solutions
100,0
%
| 1 | 100,0 % | 2 | 100,0 % | +14,31% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 1 | 100,0 % | 2 | 100,0 % | +14,31% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Maria Palasis
CEO | Chief Executive Officer | 59 | 01/01/15 |
Jason Cavalier
DFI | Director of Finance/CFO | 51 | 13/09/21 |
Richard Nieman
CTO | Chief Tech/Sci/R&D Officer | 61 | 11/07/22 |
Vineeta Belanger
CTO | Chief Tech/Sci/R&D Officer | - | 01/09/19 |
John Bishop
CTO | Chief Tech/Sci/R&D Officer | 62 | 27/02/23 |
Ellen Cavaleri
IRC | Investor Relations Contact | - | 01/01/22 |
Ronan O’Brien
LAW | General Counsel | 52 | 16/10/23 |
Corinne Noyes
PRN | Corporate Officer/Principal | 56 | 01/09/18 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Harlan Waksal
CHM | Chairman | 71 | 16/02/22 |
W. Smith
BRD | Director/Board Member | 68 | 19/11/19 |
James Tobin
BRD | Director/Board Member | 79 | 07/03/22 |
C. Merrifield
BRD | Director/Board Member | 73 | 04/09/19 |
Nancy Snyderman
BRD | Director/Board Member | 72 | 28/10/20 |
Michael Altman
BRD | Director/Board Member | 42 | 01/06/18 |
Maria Palasis
CEO | Chief Executive Officer | 59 | 01/01/15 |
Director/Board Member | 40 | 29/01/20 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 59 743 123 | 46 281 091 ( 77,47 %) | 0 | 77,47 % |
Coordinate società
Settore
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-9,92% | 282 Mln | |
+1,51% | 42,75 Mrd | |
+49,22% | 41,61 Mrd | |
+8,57% | 41,34 Mrd | |
-12,36% | 26,59 Mrd | |
+8,92% | 25,49 Mrd | |
-25,13% | 18,12 Mrd | |
+29,17% | 12,24 Mrd | |
-3,12% | 11,76 Mrd | |
+6,35% | 11 Mrd |
- Borsa valori
- Azioni
- Azione LYRA
- Società Lyra Therapeutics, Inc.